UNION therapeutics A/S (UNION), a privately-held pharmaceutical development company, announced on Thursday that it has enrolled its first patient in ADESOS, a Phase 2b dose-finding study assessing the safety and efficacy of orismilast MR tablet in adults with moderate to severe atopic dermatitis (AD).

The aim of the study is to find the appropriate dosages for Phase three studies.

The Phase 2b study is a randomised, double-blind, placebo-controlled, parallel-group study assessing the efficacy and safety of orismilast MR tablets. It is enrolling around 210 patients who will be randomised to three active doses (20mg, 30mg, and 40 mg) of orismilast compared to placebo administered twice daily. The study will be carried out at centres in Europe and the US.